1[1]The consensus trial study group:Effects of enalapril on mortality in severe congestive heart for failure:Results of the cooperative North Scandinavian Enalapril survival study.New Eng J Med,1988,316∶1429
2[2]The sol vd investigators:Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction.New Engl J Med,1992,327∶685
3[3]Pfeffer MA.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.Results of the survival after ventricular enlargement trial.New Engl J Med,1992,327∶669
4[4]Cohn JN.A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.New Engl J Med,1991,325∶303
5[5]Swedberg K.Effect of early administration of enalapril on mortality in patients with actue myocardial infarction.Result of cooperative new scandinavian enalapril survival.New Engl J Med,1992,727∶678
6[6]Lial Y,Husain A.The chymase-Angiotensin systerm in humans:Biochemistry,molecular biology and potential role in cardiovascular disease.Can J Cardiol,1995,11∶13
7[7]Jahadeesh G.Angiotensin Ⅱ receptors-antagonists,molecular biology,and signal transfuction Indian.J Exp Biol,1998,36(12)∶1171
8[8]Goodftiend T L,Elliotc M E,Cao K J,et al.Angiotensin recept ors and their antagonist.New Engl J Med,1996,334∶1649
9[9]Horinchi M,Akishita M,Dazoe VJ.Recent progress in angiotensin type Ⅱ research in the cardiovascular systerm.Hypertension,1999,33∶613
